DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Ottawa Marriott Hotel

2017年10月17日 (火) 午前 7:00 - 2017年10月18日 (水) 午後 3:00

100 Kent Street , Ottawa, ON K1P5R7 , CANADA

DIA Annual Canadian Meeting

Session 3A: Postmarket Pharmacovigilance

Session Chair(s)

Marc  Poitras, PhD, MBA

Marc Poitras, PhD, MBA

Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau

Health Canada, Canada

Adverse Drug Reactions (ADR) reporting is one of the cornerstones of pharmacovigilance. Harmonization of ADR reporting practices nationally and internationally brings its own challenges. Listen in as representatives from Health Canada and the Industry discuss the challenges associated with ADR reporting in Canada and abroad. You will learn the similarities and differences between different ADR reporting regulations in Canada, US, EU, and Asia, and their impact on the ability to monitor drug safety.

Speaker(s)

Mugdha  Chopra, DDS

Understanding Challenges in Safety Reporting in Asia – The Emerging Regulatory Market: Comparison with US and EU

Mugdha Chopra, DDS

AWINSA Life Sciences, United States

Co-Founder and Director

Hoda  Eid, PhD, MSc

Pre-Market Pharmacovigilance and its Challenges: Canadian Regulator’s Perspective

Hoda Eid, PhD, MSc

Health Canada, Canada

Manager, Office of Clinical Trials, Adverse Drug Reaction Division

Caroline  Croteau, PhD, RPh

Canadian Industry Perspective on Challenges Regarding ADR Reporting for Marketed Health Products

Caroline Croteau, PhD, RPh

Pfizer Canada Inc, Canada

Country Safety Lead

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。